세계의 mRNA 백신 및 치료제 시장 규모는 2024년 592억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 734억 달러에 이르고, 2025-2033년의 성장률(CAGR)은 2.4%를 나타낼 것으로 예측했습니다. mRNA 기반 백신이 세계적인 개발 및 수용, 신종 및 재유행 감염병에 대한 신속하고 적응력 있는 솔루션에 대한 수요 증가, 그리고 암 및 유전 질환 발병률 증가는 시장 성장을 촉진하는 주요 요인입니다.
mRNA 백신과 치료제는 신체의 세포 메커니즘을 활용하여 면역 반응을 유도합니다. mRNA(메신저 RNA)는 유전 물질의 일종입니다. COVID-19용으로 개발된 것을 포함하는 백신에서 과학자들은 스파이크 단백질로 알려진 특정 바이러스 단백질을 코딩하는 mRNA의 작은 조각을 설계합니다. mRNA는 세포에 주입되면, 세포에 침투하여 이 단백질을 생성하도록 지시하여 면역 반응을 일으킵니다. 치료적 접근법으로서 mRNA 기술은 다양한 질병을 예방하는 것뿐만 아니라 치료하는 데에도 잠재적으로 사용될 수 있습니다. mRNA 기술의 적응력과 프로그래밍 가능성은 암이나 유전 질환을 포함한 질병의 치료법을 개발하는 빠르고 유연한 방법을 제공하며, mRNA는 치료 단백질을 생성하거나 유전적 오류를 교정하도록 설계될 수 있어 이전에는 치료할 수 없었던 질병에 대한 새로운 희망을 가져다줍니다.
mRNA 백신 및 치료제 산업은 주로 COVID-19의 세계적 유행에 의해 견인되고 있습니다. 이와 함께 신흥 및 재흥 감염에 대한 신속하고 적응성이 높은 솔루션에 대한 요구가 수요를 더욱 촉진하고 있습니다. mRNA 백신은 기존 백신보다 빠르게 설계할 수 있기 때문에, 이 산업은 이러한 요구에 효과적으로 대응할 수 있는 위치에 있습니다. 또한, 암 및 유전 질환의 발병률 증가와 mRNA 치료제가 이러한 질환을 치료할 수 있는 잠재력 또한 중요한 요인입니다. 생물정보학, 합성생물학, 나노입자 전달 시스템의 지속적인 발전은 mRNA의 설계 및 전달 효율을 높여 산업 성장에 기여하고 있습니다.
만성 질환 및 감염증 증가
암, HIV, 디카 열 등의 만성 질환과 감염증이 증가함에 따라 혁신적인 치료 개입에 대한 요구가 상당히 높아지고 있습니다. 아동 수준에서 질병을 표적으로 할 수 있기 때문에 건강 관리를 제공하는 방법에 패러다임 변화를 일으킬 수 있습니다.
합성 생물학과 생물 정보학의 진보
합성 생물학과 바이오인포매틱스의 급속한 진보는 mRNA 백신 및 치료제의 개발과 개선에 도움이 되고 있습니다. 이 진보는 또한 mRNA 기술의 잠재적 응용 분야를 감염증에 그치지 않고, 유전성 질환이나 암 등으로 확대시키고 있습니다. 또한, 합성 생물학과 바이오인포매틱스의 분야에서는 최신 기술의 응용 범위와 유효성이 확대하고 있기 때문에 지속적인 개량이 시장을 견인하고 있습니다.
맞춤형 의료에 대한 수요 증가
맞춤형 의료는 환자 개인의 유전적 프로파일이나 건강상의 요구에 맞추어 치료를 실시하는 것을 목적으로 하고 있습니다. mRNA 백신과 치료를 사용자 정의하는 이 가능성은 치료 효과와 안전성 프로파일을 향상시키고 맞춤형 의료의 맥락에서 특히 매력적인 것으로 만들고 있습니다.
The global mRNA vaccines and therapeutics market size reached USD 59.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 73.4 Billion by 2033, exhibiting a growth rate (CAGR) of 2.4% during 2025-2033. The development and acceptance of mRNA-based vaccines on a global scale, the growing need for quick and adaptable solutions for emerging and re-emerging infectious diseases, and the increasing incidence of cancer and genetic diseases are some of the major factors propelling the market.
mRNA vaccines and therapeutics leverages the body's own cellular machinery to generate an immune response. mRNA, or messenger RNA, is a type of genetic material. In the context of vaccines, including those developed for COVID-19, scientists design a small piece of mRNA that codes for a specific viral protein, known as the spike protein. When injected, this mRNA enters cells and instructs them to produce this protein, triggering an immune response. As a therapeutic approach, mRNA technology can be potentially used to treat various diseases, not just prevent them. It's adaptable, programmable nature offers a fast and flexible method for creating treatments for conditions including cancer or genetic disorders, where the mRNA can be designed to produce therapeutic proteins or to correct genetic errors, offering new hope for previously untreatable conditions.
The mRNA vaccines and therapeutics industry is primarily driven by the outbreak of COVID-19 across the globe. This has encouraged the development and acceptance of mRNA-based vaccines on a global scale, demonstrating the effectiveness and rapid scalability of this technology. Along with this, the need for quick and adaptable solutions for emerging and re-emerging infectious diseases further fuels demand. As mRNA vaccines can be designed faster than traditional vaccines, this industry is positioned to address this need effectively. Additionally, the growing incidence of cancer and genetic diseases and the potential of mRNA therapeutics to treat these conditions. In addition, continuous advancements in bioinformatics, synthetic biology, and nanoparticle delivery systems are enabling more efficient design and delivery of mRNA, contributing to the industry's growth. Some of the other factors driving the market include continual improvements in healthcare infrastructure and extensive research and development activities conducted by key players.
Growing Incidence of Chronic and Infectious Diseases
With the rise of chronic and infectious diseases such as cancer, HIV, and Zika, there has been a considerable increase in the need for innovative therapeutic interventions. mRNA vaccines and therapies are unique in their ability to instruct the body to produce its own therapeutic proteins, offering a novel approach to tackling a wide range of diseases. As these treatments can target diseases at a molecular level, they represent a potential paradigm shift in how healthcare is provided. The market for these technologies is thus driven by the rising incidence of these diseases, as well as the increasing recognition among healthcare providers, patients, and researchers of the potential benefits of mRNA-based treatments.
Advancements in Synthetic Biology and Bioinformatics
The rapid pace of advancements in synthetic biology and bioinformatics has been instrumental in the development and refinement of mRNA vaccines and therapeutics. An improved understanding of genomics, enhanced capabilities in gene editing, and the use of sophisticated computational models to predict mRNA structure and behavior have all contributed to the more effective design and delivery of mRNA therapies. These advancements also expand the potential applications of mRNA technologies beyond infectious diseases to include genetic disorders and cancers, among others. The market is further driven by continual improvements in the fields of synthetic biology and bioinformatics due to the increasing scope and efficacy of modern technologies.
Rising Demand for Personalized Medicine
Personalized medicine aims to tailor treatments to the individual patient's unique genetic profile and health needs. This approach to healthcare represents a significant departure from the one-size-fits-all paradigm and has been gaining traction in recent years. mRNA technologies hold significant promise in this regard due to their inherent ability to be designed for specific genetic profiles or to target specific disease variants. This potential to customize mRNA vaccines and treatments is improving their therapeutic efficacy and safety profile, making them particularly attractive in the context of personalized medicine. This is propelling the demand for personalized medicine. As more healthcare providers and patients become aware of the benefits of personalized medicine, the demand for mRNA technologies is escalates, thereby impacting the market.
Conventional non-amplifying mRNA-based vaccines dominate the market
The growing global health concerns about emerging infectious diseases and the need for quick vaccine development are majorly driving the market segment. These vaccines can be quickly produced and modified, making them ideally suited for combatting rapidly mutating diseases such as influenza and COVID-19. Additionally, the recent success of mRNA vaccines is leading to an increased acceptance and trust in this technology, influencing the market demand. Along with this, the rising prevalence of cancer, and the potential of mRNA vaccines for cancer treatment, also act as a significant market driver. Moreover, continual technological advancements and significant investments in research and development of mRNA technology play a crucial role in shaping the market.
The market for conventional non-amplifying mRNA-based vaccines has also seen rapid growth due to the acceptance and adoption of mRNA technology, demonstrating its ability to rapidly develop effective vaccines against novel pathogens. This has led to increased investment in mRNA research and development, and growing confidence in its potential. Additionally, the relatively quick and cost-effective production process of mRNA vaccines, as well as their versatility for targeting a variety of diseases. As diseases evolve and new pathogens emerge, the capacity for rapid design modifications is becoming an increasingly important market driver. Besides, there is a rising focus on personalized medicine, and mRNA vaccines have the potential to be tailored to individual patient needs, such as for cancer immunotherapy, providing another strong growth driver in the market.
Bioengineered vaccine dominate the market
Bioengineered vaccines' ability to be quickly designed and mass-produced in response to new viral threats positions them as a vital tool in global health security, fostering increased investment and demand. In addition, the ongoing research exploring the potential of mRNA therapeutics beyond vaccines, such as in cancer immunotherapy and genetic diseases, broadens the industry's scope. Moreover, policy support from governments and collaborations between pharma-biotech companies contribute to the acceleration of mRNA-based research, development, and commercialization.
On the other hand, the broad therapeutic potential of gene therapies for a wide array of genetic, oncologic, and chronic diseases are expected to augment the growth of the segment. Technological advancements in gene editing tools, including CRISPR-Cas9, have facilitated the development and refinement of mRNA-based gene therapies. The growing prevalence of genetic disorders and the urgent need for effective treatments have also spurred interest and investment in this sector. Besides this, favorable government policies, increased healthcare expenditure, and strategic collaborations among biotech and pharmaceutical companies accelerate this industry's growth.
The market for gene transcription in the mRNA vaccines and therapeutics industry is further fueled by the creation of innovative treatment modalities for various diseases. Along with this, advancements in genomics and transcriptomics technology are enhancing our ability to manipulate and understand gene transcription, further driving the market. In addition, the rise in the prevalence of diseases, including cancer, where abnormal gene transcription plays a key role, necessitates continued investment and exploration in this field.
In-house manufacturing dominate the mRNA vaccines and therapeutics market
The potential of mRNA technologies to treat a broad array of diseases beyond infectious diseases, including cancer, is acting as a catalyst for companies to invest in their own manufacturing capabilities. The need for supply chain security and independence, the desire to control quality standards, and the potential cost savings over time through economies of scale also play a significant role in driving the move towards in-house manufacturing. In addition, advancements in manufacturing technologies and processes are making in-house production more feasible and cost-effective, even for smaller biotech companies.
On the contrary, the market drivers for outsourced manufacturing in the mRNA vaccines and therapeutics industry are predominantly shaped by the rapid advancement in biotechnologies, coupled with the global urgency to respond to emerging health crises. One key market driver is the need for speed and scalability in vaccine production to meet global demand, particularly in times of health crises. Outsourced manufacturing allows for quicker ramp-up of production capacity. Additionally, the complexity and specialized requirements of mRNA vaccine production, including high-precision cold-chain logistics and proprietary lipid nanoparticle technology, demand a level of expertise that not all pharmaceutical companies possess. This drives the demand for specialized contract manufacturing organizations (CMOs) that have the necessary technology and know-how.
Infectious disease dominate the market
The mRNA vaccines and therapeutics industry for infectious diseases is majorly influenced by the unprecedented global demand for effective vaccines to combat emergent infectious diseases. This is largely due to the unique ability of mRNA vaccines to be rapidly designed and produced in response to new viral threats. Furthermore, the relatively high efficacy and favorable safety profile of approved mRNA vaccines, such as those from Moderna and Pfizer-BioNTech, is supporting the confidence in this innovative technology.
On the other hand, the cancer application is driven due to the growing global burden of cancer, with increasing incidence rates across various age groups. Along with this, the growing need for effective treatments is propelling research and innovation in mRNA therapeutics. mRNA vaccines have gained substantial attention due to their success in tackling infectious diseases. Technological advancements in bioinformatics and nanotechnology enable the fine-tuning of mRNA vaccines for cancer-specific antigens, further driving this market.
Hospitals and clinics dominate the market
Numerous factors for hospitals and clinics end-user in the mRNA vaccines and therapeutics industry includes the necessity for efficient, fast-developing vaccines to combat existing and emerging infectious diseases, which was underscored by the successful implementation of mRNA technology. Along with this, the increasing prevalence of cancer and genetic diseases also raises the demand, as mRNA therapeutics provide innovative, personalized treatment approaches. Additionally, the growing awareness and acceptance of mRNA vaccines and therapeutics among medical practitioners and patients also contributes to this growth.
The market drivers for research organizations in the mRNA vaccines and therapeutics industry are largely defined by the growing prevalence of infectious diseases and cancers, increased investment in R&D, and rapid advancements in biotechnology. Additionally, the shifting preference towards personalized medicine, with mRNA therapeutics playing a critical role in this evolution. Governmental support and funding for mRNA research, coupled with a strong pipeline of mRNA-based therapeutics and vaccines in clinical trials, are also significant market drivers.
Europe exhibits a clear dominance, accounting for the largest market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, United Kingdom, France, Italy, Spain, Russia and others ); Asia Pacific (Japan, China, Australia, South Korea, India, Indonesia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
The mRNA vaccines and therapeutics industry in Europe is driven by ongoing investment in research and development fuels the expansion of the mRNA portfolio beyond vaccines into potential cures for cancer, genetic diseases, and other chronic conditions, further propelling the market growth. The presence of seamless approval processes, implemented during the pandemic, also act as a catalyst, facilitating quicker route-to-market and uptake for novel mRNA products. Moreover, the strong presence of key industry players in the region, underpin the robust growth of the mRNA vaccines and therapeutics market.
On the contrary, Asia Pacific is estimated to expand further in this domain due to the rising prevalence of infectious diseases, and the increased awareness of the need for preventative measures. Technological advancements are also key, as growing research and development capabilities in countries, such as China and India are accelerating the pace of innovative mRNA therapeutics. Additionally, the region's large population base provides a massive potential demand for these vaccines.
The global mRNA vaccines and therapeutics market is experiencing significant growth due to the increasing investments in research and development (R&D) to create more effective vaccines and therapeutics, as well as to expand the use of mRNA technology beyond vaccines to a broader range of therapeutic applications, including cancer treatment, cardiovascular diseases, and genetic disorders. Along with this, companies are forging partnerships and collaborations with academic institutions, biotech firms, and other pharmaceutical companies to accelerate the development of mRNA vaccines and therapeutics. This approach helps to pool resources, share knowledge, and diversify risk. In addition, companies are working closely with regulatory bodies across the globe to ensure their products meet safety and efficacy requirements. They are conducting extensive clinical trials and are in constant communication with authorities to secure approvals for their products. Furthermore, companies are also investing in efforts to educate the public about the safety and efficacy of mRNA vaccines, to overcome vaccine hesitancy and misinformation.